188 related articles for article (PubMed ID: 32923124)
21. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Ready N
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
[TBL] [Abstract][Full Text] [Related]
22. Repeated dose intramuscular injection of the CIMAvax-EGF vaccine in Sprague Dawley rats induces local and systemic toxicity.
Mancebo A; Casacó A; González B; Ledón N; Sorlozabal J; León A; Gómez D; González Y; Bada AM; González C; Arteaga ME; Ramírez H; Fuentes D
Vaccine; 2012 May; 30(22):3329-38. PubMed ID: 22433960
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials.
González G; Crombet T; Neninger E; Viada C; Lage A
Hum Vaccin; 2007; 3(1):8-13. PubMed ID: 17204867
[TBL] [Abstract][Full Text] [Related]
24. Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario.
Flores Vega YI; Páramo González DL; Alsina Sarmiento SC; Alsina Tul LE; Inguanzo Valdés IB; Rodríguez Machado J; Elejalde Larrinaga Á; Flores Rodríguez JE; Lamadrid García J; Corrales Otero D; Ropero Toirac R; Crombet Ramos T; Gracia Medina EA
J Cancer; 2023; 14(5):874-879. PubMed ID: 37056397
[No Abstract] [Full Text] [Related]
25. The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer.
Crombet Ramos T; Santos Morales O; Dy GK; León Monzón K; Lage Dávila A
Front Oncol; 2021; 11():639745. PubMed ID: 34211836
[TBL] [Abstract][Full Text] [Related]
26. Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer.
Vollebergh MA; Kappers I; Klomp HM; Buning-Kager JC; Korse CM; Hauptmann M; de Visser KE; van den Heuvel MM; Linn SC
J Thorac Oncol; 2010 Dec; 5(12):1939-48. PubMed ID: 21102259
[TBL] [Abstract][Full Text] [Related]
27. A Novel Combined Conjugate Therapeutic Cancer Vaccine, Recombinant EGF-CRM197, in Patients With Advanced Solid Tumors: A Phase I Clinical Study.
Xiong AW; Fang JM; Ren SX; Li W; Wang J; Zhao Y; Chen GY; Xu Q; Zhou CC
Front Oncol; 2021; 11():745699. PubMed ID: 34804932
[TBL] [Abstract][Full Text] [Related]
28. Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine.
Morera Y; Sánchez J; Bequet-Romero M; Selman-Housein KH; de la Torre A; Hernández-Bernal F; Martín Y; Garabito A; Piñero J; Bermúdez C; de la Torre J; Ayala M; Gavilondo JV
Vaccine; 2017 Jun; 35(28):3582-3590. PubMed ID: 28536029
[TBL] [Abstract][Full Text] [Related]
29. CIMAvax EGF vaccine for stage IIIb/IV non-small cell lung carcinoma.
Cheng JY; Kananathan R
Hum Vaccin Immunother; 2012 Dec; 8(12):1799-801. PubMed ID: 22906936
[TBL] [Abstract][Full Text] [Related]
30. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
31. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
[TBL] [Abstract][Full Text] [Related]
32. Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer.
Suárez GM; Añé-Kourí AL; González A; Lorenzo-Luaces P; Neninger E; Salomón EE; Cordero L; Catalá M; Ledón N; Pereira K; Sánchez MG; García B; Crombet T; Mazorra Z; Saavedra D; Lage A
Cancer Immunol Immunother; 2021 Jun; 70(6):1735-1743. PubMed ID: 33388995
[TBL] [Abstract][Full Text] [Related]
33. Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells.
Codony-Servat J; García-Roman S; Molina-Vila MÁ; Bertran-Alamillo J; Giménez-Capitán A; Viteri S; Cardona AF; D'Hondt E; Karachaliou N; Rosell R
J Thorac Oncol; 2018 Sep; 13(9):1324-1337. PubMed ID: 29751136
[TBL] [Abstract][Full Text] [Related]
34. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
35. Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants.
Sánchez Ramírez J; Morera Díaz Y; Bequet-Romero M; Hernández-Bernal F; Selman-Housein Bernal KH; de la Torre Santos A; Santiesteban Álvarez ER; Martín Bauta Y; Bermúdez Badell CH; de la Torre Pupo J; Gavilondo JV; ; Ayala Avila M
BMC Immunol; 2017 Jul; 18(1):39. PubMed ID: 28747172
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy.
Gonzalez G; Crombet T; Torres F; Catala M; Alfonso L; Osorio M; Neninger E; Garcia B; Mulet A; Perez R; Lage R
Ann Oncol; 2003 Mar; 14(3):461-6. PubMed ID: 12598354
[TBL] [Abstract][Full Text] [Related]
37. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
Bonomi PD; Gandara D; Hirsch FR; Kerr KM; Obasaju C; Paz-Ares L; Bellomo C; Bradley JD; Bunn PA; Culligan M; Jett JR; Kim ES; Langer CJ; Natale RB; Novello S; Pérol M; Ramalingam SS; Reck M; Reynolds CH; Smit EF; Socinski MA; Spigel DR; Vansteenkiste JF; Wakelee H; Thatcher N
Ann Oncol; 2018 Aug; 29(8):1701-1709. PubMed ID: 29905778
[TBL] [Abstract][Full Text] [Related]
38. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
39. Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
Tarhini AA; Rafique I; Floros T; Tran P; Gooding WE; Villaruz LC; Burns TF; Friedland DM; Petro DP; Farooqui M; Gomez-Garcia J; Gaither-Davis A; Dacic S; Argiris A; Socinski MA; Stabile LP; Siegfried JM
Cancer; 2017 Aug; 123(15):2936-2944. PubMed ID: 28472537
[TBL] [Abstract][Full Text] [Related]
40. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.
Guo XF; Zhu XF; Cao HY; Zhong GS; Li L; Deng BG; Chen P; Wang PZ; Miao QF; Zhen YS
Oncotarget; 2017 Apr; 8(16):27286-27299. PubMed ID: 28460483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
